Novartis (NVS) Acquires Majority Stake in Zhejiang Tianyuan Bio-Pharmaceutical for $125 Million
Hard To Treat Diseases (OTC: HTDS) announced that Novartis (NYSE: NVS), is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million.
Novartis of Switzerland will begin a five-year, $1 billion China initiative with two aims: the company will dramatically increase its investment in its China R&D facility, and it will seek to make China one its top three markets worldwide.
HTDS' Chinese subsidiary, Mellow Hope, is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical for International marketing and sales. Zhejiang Tianyuan Bio-pharmaceutical has been granted a H1N1 license on September 24, 2009 by the Chinese government agency, SFDA.
[SM]
Related Categories
Corporate NewsStocks Mentioned
Comments
ugg for sale
Dunk SB Shoes air max 2009 nike air max 2009 Nike Air Max cardy ugg ugg classic boots UGG Boots UK UGG Boots Sale ugg for sale ugg shoes uggs shoes bailey button uggs
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

mbt shoes
mbt shoes on Nov 10, 2009 06:14 AMtimberland pro boots Womens Roll-Top Boots Womens High Top Boots Womens 6 Inch Boots jack wills Apparel jackwills billy jack wills jack wills mbt trainers mbt shoes mbt shoe mbt sale